Innovation ADC Therapy for Breast Cancer with Remission Rate over 50% - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Innovation ADC Therapy for Breast Cancer with Remission Rate over 50%

Description:

The DS-8201 is designed with the first three proprietary ADC technologies and is a smart chemotherapy solution. It connects a humanized HER2 ADC antibody to a novel topoisomerase I inhibitor payload through a four-tire ADC linker. Compared to traditional chemotherapy, it can target and deliver chemotherapy within cancer cells, thereby reducing systemic exposure to cytotoxic payload (or chemotherapy). Learn more about ADC at – PowerPoint PPT presentation

Number of Views:6
Slides: 11
Provided by: BellaSmith2018

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Innovation ADC Therapy for Breast Cancer with Remission Rate over 50%


1
Innovation ADC Therapy for Breast Cancer with
Remission Rate over 50
www.creative-biolabs.com/adc
2
Recently, Daiichi Sankyo announced its clinical
safety and efficacy data based on a long-term I
phase clinical trial for 241 HER2-positive breast
cancer patients. These results were announced at
the 2018 American Society of Clinical Oncology
(ASCO) annual meeting. About one-fifth of breast
and gastric cancers have overexpressed HER2, a
tyrosine kinase receptor growth-promoting protein
found on the surface of certain invasive cancer
cells. After the progression of many
HER2-positive tumors, some existing approved
therapies have been unable to continue to
effectively control the disease and have not been
available after treatment with trastuzumab,
pertuzumab, and T-DM1. The standard of care for
HER2-positive tumors. These patients are faced
with unmet medical needs.
3
DS-8201 is the first Tri-Commercial primary ADC
product. ADC is a type of cancer targeting drug
that can deliver cytotoxic chemotherapy (payload)
to cancer cells by attaching monoclonal
antibodies that bind to specific targets on
cancer cells. The DS-8201 is designed with the
first three proprietary ADC technologies and is a
smart chemotherapy solution. It connects a
humanized HER2 ADC antibody to a novel
topoisomerase I inhibitor payload through a
four-tire ADC linker. Compared to traditional
chemotherapy, it can target and deliver
chemotherapy within cancer cells, thereby
reducing systemic exposure to cytotoxic payload
(or chemotherapy).
4
The Phase 1 study announced this time is a
two-part open-label study evaluating the efficacy
of DS-8201 in patients with advanced/unresectable
or metastatic solid tumors who are resistant or
intolerant to standard treatment. The primary end
point of this study dose escalation phase was the
safety and tolerability of DS-8201 and the
determination of the maximum tolerated dose. The
results of this update are as follows. A subgroup
analysis of 34 patients with HER2 low-expressing
metastatic breast cancer showed that the overall
response rate (ORR) was 50.0 and the disease
control rate was 85.3 in patients using
DS-8201 A subgroup analysis of 99 HER2-positive
metastatic breast cancer patients treated with
T-DM1, trastuzumab, and pertuzumab demonstrated
an ORR of 54.5 with DS-8201 and a disease-free
rate of 93.9. The remission and disease
control of DS-8201 was also observed in
HER2-positive gastric cancer and other solid
tumors including colorectal cancer and
non-small-cell lung cancer.
5
What is DS-8201
DS-8201 is the first Tri-Commercial primary ADC
product. ADC is a type of cancer targeting drug
that can deliver cytotoxic chemotherapy (payload)
to cancer cells by attaching monoclonal
antibodies that bind to specific targets on
cancer cells. The DS-8201 is designed with the
first three proprietary ADC technologies and is a
smart chemotherapy solution. It connects a
humanized HER2 ADC antibody to a novel
topoisomerase I inhibitor payload through a
four-tire ADC linker. Compared to traditional
chemotherapy, it can target and deliver
chemotherapy within cancer cells, thereby
reducing systemic exposure to cytotoxic payload
(or chemotherapy).
6
(No Transcript)
7
(No Transcript)
8
Established in 2004, Creative Biolabs is highly
specialized in advanced antibody biochemistry and
engineering, including ADC customs products. With
more than a decade of exploration and expansion,
our current research and service capacity covers
the entire new drug discovery and antibody
conjugation service, which ranges from early
discovery, pre-clinical evaluations, cGMP
manufacturing, dar conjugation to clinical
trials. As an international cooperation, Creative
Biolabs has established multiple offices all
around the globe with more than 200 well-trained
full-time scientists and technicians, who work
closely with our customers and research partners
to develop new medicines for a better, healthier
world.
Creative Biolabs
9
Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA
Email marketing_at_creative-biolabs.com
10
Thank You
www.creative-biolabs.com/adc
About PowerShow.com